Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
Authors
Keywords
-
Journal
JOURNAL OF INFECTIOUS DISEASES
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-05-07
DOI
10.1093/infdis/jiac188
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
- (2022) Rolando Pajon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
- (2022) Peter B. Gilbert et al. SCIENCE
- Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2–experienced individuals
- (2022) Marie I. Samanovic et al. Science Translational Medicine
- COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021
- (2022) Tomás M. León et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Adaptive immunity to SARS-CoV-2 and COVID-19
- (2021) Alessandro Sette et al. CELL
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
- (2021) Jennifer M. Dan et al. SCIENCE
- Sex differences in immune responses
- (2021) Takehiro Takahashi et al. SCIENCE
- Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report
- (2021) Kai Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
- (2021) Laurence Chu et al. VACCINE
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination
- (2021) Rishi R. Goel et al. Science Immunology
- Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273
- (2021) Deborah Steensels et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays
- (2021) Anton M. Sholukh et al. JOURNAL OF CLINICAL MICROBIOLOGY
- A Rapid Assay for SARS-CoV-2 Neutralizing Antibodies That Is Insensitive to Antiretroviral Drugs
- (2021) Deli Huang et al. JOURNAL OF IMMUNOLOGY
- BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
- (2021) Ugur Sahin et al. NATURE
- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
- (2021) Angela Choi et al. NATURE MEDICINE
- Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
- (2021) Kashif Ali et al. NEW ENGLAND JOURNAL OF MEDICINE
- Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
- (2021) Meagan P. O’Brien et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
- (2021) Hana M. El Sahly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
- (2021) Amarendra Pegu et al. SCIENCE
- Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
- (2021) Kizzmekia S. Corbett et al. SCIENCE
- A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval
- (2021) Brian Grunau et al. CLINICAL INFECTIOUS DISEASES
- Protective Immunity after Natural Infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) – Kentucky, USA, 2020
- (2021) Kevin B. Spicer et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
- (2021) Shuo Feng et al. NATURE MEDICINE
- Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
- (2021) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection
- (2020) Paul Kellam et al. JOURNAL OF GENERAL VIROLOGY
- SARS-CoV-2 infection protects against rechallenge in rhesus macaques
- (2020) Abishek Chandrashekar et al. SCIENCE
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals
- (2020) Davide F. Robbiani et al. NATURE
- Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population
- (2020) Sabra L. Klein et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
- (2020) Evan J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Correlates of protection against SARS-CoV-2 in rhesus macaques
- (2020) Katherine McMahan et al. NATURE
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
- (2020) Ventura A. Simonovich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Updates on immunologic correlates of vaccine-induced protection
- (2019) Stanley A. Plotkin VACCINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search